B-Cell Neoplasia

Paolo Ghia

ghia paolo

Email: ghia.paolo@hsr.it
Location: DIBIT1, Floor 1, Room 38

Deputy Director, Division of Experimental Oncology
Head, B-cell Neoplasia Unit
Head, Chronic Lymphocytic Leukemia Unit
Associate professor, Università Vita Salute San Raffaele

Paolo Ghia received his MD from the University of Torino, Italy, followed by a residency in Internal Medicine. He received his PhD working at the Basel Institute for Immunology, Basel, Switzerland, where he studied the development of normal human B lymphocytes. He moved to the Dana-Farber Cancer Institute, Harvard Medical School, Boston, where he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly of follicular lymphoma. He is now working in Milano, as Full Professor in Oncology at the Università Vita-Salute San Raffaele; and Deputy Chairman of the Division of Experimental Oncology, at IRCCS Ospedale San Raffaele. He is Head of the Laboratory of B-Cell Neoplasia and Director of the Chronic Lymphocytic Leukemia Unit , where he is National Coordinator or Principal Investigator in clinical trials in CLL and related disorders, including phase 1 studies.

His research interest is the study of the molecular and cellular mechanisms acting in the natural history of Chronic Lymphocytic Leukemia (CLL), including Monoclonal B-cell Lymphocytosis (MBL) with the overall aim of translating the knowledge into the definition of more reliable prognostic markers and more targeted therapies. On these topics he has published over 230 manuscripts in peer-reviewed journals. He is President of the European Research Initiative on CLL (ERIC), collaborating to the guidelines for the detection of Minimal Residual Disease (MRD) for the analysis of the mutational status of the immunoglobulin (IGHV) genes and of the TP53 gene aberrations.

He is also a member of the WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies for the topic Chronic Lymphocytic Leukemia, MBL, and PLL and associate Editor for CLL at Hemasphere, the official Journal of the European Hematology Association (EHA).